Document is current
Any future updates will be listed below
-
Authors
Choi, Jae-Yeon http://orcid.org/0000-0002-9853-0987
Gihaz, Shalev http://orcid.org/0000-0001-7292-0808
Munshi, Muhammad http://orcid.org/0000-0002-6052-7002
Singh, Pallavi http://orcid.org/0000-0003-2318-5960
Vydyam, Pratap
Hamel, Patrice
Adams, Emily M. http://orcid.org/0000-0002-4382-6166
Sun, Xinghui
Khalimonchuk, Oleh
Fuller, Kevin
Ben Mamoun, Choukri http://orcid.org/0000-0001-5028-1400
-
Funding
Funding for this research was provided by:
Blavatnik Family Foundation
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI123321, AI138139, AI152220, and AI136118)
- License Information
-
More Information
Article History
Received: 10 November 2023
Accepted: 17 July 2024
First Online: 23 July 2024
Competing interests
: The authors declare the following competing interests. C.B.M. is the founder of Curatix, which focuses on the development of anti-infectives. J.C.Y. conducted this work while an Associate Research Scientist at Yale. He is currently a Scientific Director Curatix. All other authors declare that they have no conflict of interest with the content of this article. A patent application on the use of the PAMS strategy to potentiate antifungal drugs has been submitted by CBM.
